Most notably, in HD, laduviglusib has demonstrated its potential in inhibiting the proteolysis of calpastatin protein bodies, impeding Drp1 recruitment to mitochondria, and reducing mitochondrial fragmentation [24]. Here, DNM1L is linked to Huntington disease.